GlassScriptPhysician profile
Michael A Lobatz
NPI 1619912078
$1,659.29
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $218 · 2021: $119 · 2022: $136 · 2023: $70.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $139.79 | 2019 | |
| Amgen INC. | $122.65 | 2019-2020 | |
| Horizon Therapeutics Plc | $119.31 | 2021 | |
| Allergan, INC. | $109.67 | 2020 | |
| Merz North America, INC. | $102.66 | 2019 | |
| Avanir Pharmaceuticals, INC. | $88.54 | 2019-2022 | |
| Boston Scientific Corporation | $86.66 | 2019 | |
| Biogen, INC. | $82.59 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $72.99 | 2019-2022 | |
| Genzyme Corporation | $68.25 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $62.00 | 2019-2023 | |
| Medtronic Vascular, INC. | $57.62 | 2019 | |
| Eisai INC. | $51.89 | 2019 | |
| Greenwich Biosciences, INC. | $50.89 | 2019 | |
| Ge Healthcare | $43.10 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $39.48 | 2019 | |
| Medtronic, INC. | $37.11 | 2023 | Sensight |
| Aquestive Therapeutics, INC. | $31.83 | 2019 | |
| Promius Pharma LLC | $28.31 | 2019 | |
| Kyowa Kirin, INC. | $27.93 | 2019-2020 | |
| Tersera Therapeutics LLC | $26.92 | 2019 | |
| Neurocrine Biosciences, INC. | $24.40 | 2022 | |
| Acorda Therapeutics, INC | $24.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.97 | 2019 | |
| Argenx US, INC. | $18.88 | 2023 | Vyvgart |
| Lundbeck LLC | $18.33 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.22 | 2019 | |
| Tanabe Pharma America, INC. | $16.23 | 2019 | |
| Csl Behring | $15.75 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.88 | 2019 | |
| Zyla Life Sciences, INC. | $12.78 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.45 | 2022 | |
| Scilex Pharmaceuticals INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lobatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.